Adiponectin and its receptors in chronic hepatitis B patients with metabolic syndrome in China

Hepato-Gastroenterology

Volumn 59, Issue 118, 2012, Pages 1735-1743

  Li, Xin ^a   Ren, Na ^a   Ling, Wei ^a   Chen, FengXin ^a   Zhang, WeiYan ^a   Fan, XiaoLing ^a   Tian, MeiMei ^a   Zhang, Ting ^a   Li, Ben ^a   Pfeffer, Lawrence M ^b   Wu, Hao ^c   Zhang, JinQian ^a  

^a CAPITAL MEDICAL UNIVERSITY   (China)

^b UNIVERSITY OF TENNESSEE HEALTH SCIENCE CENTER   (United States)

^c CAPITAL MEDICAL UNIVERSITY   (China)

Author keywords

Adiponectin; Chronic hepatitis B; Insulin resistance; Metabolic syndrome; Receptor

Indexed keywords

ADIPONECTIN; ADIPONECTIN RECEPTOR 2; GAMMA GLUTAMYLTRANSFERASE; HEPATITIS B(E) ANTIGEN; LACTATE DEHYDROGENASE;

ADULT; ARTICLE; CHINA; DIABETES MELLITUS; DISEASE COURSE; DISEASE SEVERITY; FATTY LIVER; FEMALE; GAMMA GLUTAMYL TRANSFERASE BLOOD LEVEL; HEPATITIS B; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; INSULIN SENSITIVITY; LACTATE DEHYDROGENASE BLOOD LEVEL; MAJOR CLINICAL STUDY; MALE; METABOLIC SYNDROME X; PATHOGENESIS; PRIORITY JOURNAL; PROTEIN EXPRESSION;

ADIPONECTIN; ADULT; ANALYSIS OF VARIANCE; BIOLOGICAL MARKERS; BIOPSY; BODY MASS INDEX; CHI-SQUARE DISTRIBUTION; CHINA; DOWN-REGULATION; FATTY LIVER; FEMALE; HEPATITIS B, CHRONIC; HUMANS; IMMUNOHISTOCHEMISTRY; INSULIN RESISTANCE; LINEAR MODELS; LIVER; LOGISTIC MODELS; MALE; METABOLIC SYNDROME X; MIDDLE AGED; REAL-TIME POLYMERASE CHAIN REACTION; RECEPTORS, ADIPONECTIN; RISK ASSESSMENT; RISK FACTORS; RNA, MESSENGER;

EID: 84867740042     PISSN: 01726390     EISSN: None     Source Type: Journal    
DOI: 10.5754/hge10717     Document Type: Article

References (62)

1. Beck-Nielsen H, Hother-Nielsen O, LeRoith D, et al: Philadelphia: Lippincott Williams & Wilkins, Obesity in type 2 diabetes mellitus. Diabetes Mellitus 2004; 857-868.
2. Gu DF, Reynolds K, Yang WJ, et al.: The prevalence of metabolic Syndrome in the general adult population aged 35-74 years in China. Chin J Diabetes 2005; 13:181-186.
3. Arao M, Murase K, Kusakabe A, et al.: Prevalence of diabetes mellitus in Japanese patients infected chronically with hepatitis C virus. J Gastroenterol 2003; 38:355-360. (Pubitemid 36626271)
4. Custro N, Carrocio A, Ganci A, et al.: Glycemic homeostasis in chronic viral hepatitis and liver cirrhosis. Diabetes Metab 2001; 27:476-481. (Pubitemid 32852456)
5. Petrides AS, Vogt C, Schulze-Berge D, et al.: Pathogenesis of glucose intolerance and diabetes mellitus in cirrhosis. Hepatology 1994; 19:616-627. (Pubitemid 24066891)
6. Antonelli A, Ferri C, Fallahi P, et al.: Hepatitis C virus infection evidence for an association with type 2 diabetes. Diabetes Care 2005; 28:2548-2550. (Pubitemid 41384312)
7. Petit JM, Bour JB, Galland-Jos C, et al.: Risk factors for diabetes mellitus and early insulin resistance in chronic hepatitis C. J Hepatol 2001; 35:279-283. (Pubitemid 32803485)
8. Thuluvath PJ, John PR: Association between hepatitis C, diabetes mellitus, and race: a case-control study. Am J Gastroenterol 2003; 98:438-441. (Pubitemid 36232396)
9. Younossi ZM, McCullough AJ, Ong JP, et al.: Obesity and non-alcoholic fatty liver disease in chronic hepatitis C. J Clin Gastroenterol 2004; 38:705-709. (Pubitemid 39096803)
10. Adinolfi L E, Gambardella M, Andreana A, et al.: Steatosis accelerates the progression of liver damage of chronic hepatitis C patients and correlates with specific HCV genotype and visceral obesity. Hepatology 2001; 33(6):1358-1364. (Pubitemid 32496971)
11. Lee WM: Hepatitis B virus infection. N Engl J Med 1997; 337(24):1733-1745.
12. Lau JY, Wright TL: Molecular virology and pathogenesis of hepatitis B. Lancet 1993; 342(8883):1335-1340. (Pubitemid 23345183)
13. Wands JR, Blum HE: Primary hepatocellular carcinoma. N Engl J Med 1991; 325(10):729-731.
14. Berg AH, Combs TP, Scherer PE: ACRP30/adiponectin: an adipokine regulating glucose and lipid metabolism. Trends Endocrinol Metab 2002; 13:84-89. (Pubitemid 36740452)
15. Steppan CM, Lazar MA: Resistin and obesity-associated insulin resistance. Trends Endocrinol Metab 2002; 13:18-23. (Pubitemid 36734011)
16. Pellme F, Smith U, Funahashi T, et al.: Circulating adiponectin levels are reduced in non-obese but insulin-resistant first-degree relatives of type 2 diabetic patients. Diabetes 2003; 52:1182-1186. (Pubitemid 36523354)
17. Tschritter O, Fritsche A, Thamer C, et al.: Plasma adiponectin concentrations predict insulin sensitivity of both glucose and lipid metabolism. Diabetes 2003; 52:239-243. (Pubitemid 36173174)
18. Yokota T, Oritani K, Takahashi I, et al.: Adiponectin, a new member of the family of soluble defense, collagens, negatively regulates the growth of myelomonocytic progenitors and the functions of macrophages. Blood 2000; 96:1723-1732. (Pubitemid 30661055)
19. Berg AH, Combs TP, Du XL, Brownlee M, Scherer P: The adipocytes secreted protein Acrp30 enhances hepatic insulin action. Nat Med 2001; 7:947-953. (Pubitemid 32756433)
20. Ouchi N, Kihara S, Arita Y, et al.: Adipocyte-derived plasma protein, adiponectin, suppresses lipid accumulation and class A scavenger receptor expression in human monocyte-derived macrophages. Circulation 2001; 103:1057-1063. (Pubitemid 32200177)
21. Wolf AM, Wolf D, Rumpold H, Enrich B, Tilg H: Adiponectin induces the anti-inflammatory cytokines IL-10 and IL-1RA in human leukocytes. Biochem Biophys Res Commun 2004; 323:630-635. (Pubitemid 39221142)
22. Xu AM, Wang Y, Keshaw H, Xu LY, Lam KSL, Cooper GJS: The fat-derived hormone adiponectin alleviates alcoholic and non-alcoholic fatty liver diseases in mice. J Clin Invest 2003; 112:91-100. (Pubitemid 38056380)
23. Xu A, Wang Y, Keshaw H, et al.: The fat-derived hormone adiponectin alleviates alcoholic and nonalcoholic fatty liver diseases in mice. J Clin Invest 2003; 112:91-100. (Pubitemid 38056380)
24. Kaser S, Moschen A, Cayon A, et al.: Adiponectin and its receptors in non-alcoholic steatohepatitis. Gut 2005; 54(1):117-121. (Pubitemid 40007229)
25. Jonsson JR, Moschen AR, Hickman IJ, et al.: Adiponectin and its receptors in patients with chronic hepatitis C. J Hepatology 2005; 43:929-936. (Pubitemid 41627976)
26. Matthews DR, Hosker JP, Rudenski AS, et al.: Homeostasis model assessment-insulin resistance and beta-cell function from fasting plasma-glucose and insulin concentrations in man. Diabetologia 1985; 28:412-419. (Pubitemid 15018832)
27. Bonora E, Saggiani F, Targher G, et al.: Homeostasis model assessment closely mirrors the glucose clamp technique in the assessment of insulin sensitivity-studies in subjects with various degrees of glucose tolerance and insulin sensitivity. Diabetes Care 2000; 23:57-63. (Pubitemid 30022895)
28. Ishak K, Baptista A, Bianchi L, et al.: Histological grading and staging of chronic hepatitis. J Hepatol 1995; 22:696-699.
29. Scheuer PJ: Classification of chronic viral hepatitis: a need for reassessment. J Hepatol 1991; 13:372-374.
30. Walsh MJ, Vanags DM, Clouston AD, et al.: Steatosis and liver cell apoptosis in chronic hepatitis C: a mechanism for increased liver injury. Hepatology 2004; 39:1230-1238. (Pubitemid 38569044)
31. Park YW, Zhu S, Palaniappan L, et al.: The metabolic syndrome: prevalence and associated risk factor findings in the US population from the Third National Health and Nutrition Examination Survey, 1988-1994. Arch Int Med 2003; 163:427-436. (Pubitemid 36241019)
32. Lidfeldt J, Nyberg P, Nerbrand C, et al.: Socio-demographic and psychosocial factors are associated with features of the metabolic syndrome. The Women's Health in the Lund Area (WHILA) study. Diab Obes Metabol 2003; 5:106-112. (Pubitemid 36372502)
33. Park HS, Oh SW, Cho SI, et al.: The metabolic syndrome and associated lifestyle factors among South Korean adults. Int J Epidemiol 2004; 33:328-336. (Pubitemid 38578831)
34. Park YW, Zhu S, Palaniappan L, et al.: The metabolic syndrome: prevalence and associated risk factor findings in the US population from the Third National Health and Nutrition Examination Survey, 1988-1994. Arch Int Med 2003; 163:427-436. (Pubitemid 36241019)
35. Stone NJ: Focus on lifestyle change and the metabolic syndrome. Endocrinol Metab Clin 2004; 33:493-508.
36. Wamala SP, Lynch J, Horsten M, et al.: Education and the metabolic syndrome in women. Diabetes Care 1999; 22:1999-2003. (Pubitemid 30433979)
37. Hui JM, Sud A, Farrell GC, et al.: Insulin resistance is associated with chronic hepatitis C virus infection and fibrosis progression (corrected). Gastroenterology 2003; 125:1695-1704. (Pubitemid 37500434)
38. Noriyuki N, Drph K, Scd K: Serum γ-Glutamyltransferase and risk of metabolic syndrome and type 2 diabetes in middle-aged Japanese men. Diabetes Care 2004; 27:1427-1432.
39. Perry IJ, Wannamethee SG, Shaper AG: Prospective study of serum-glutamyltransferase and risk of NIDDM. Diabetes Care 1998; 21:732-737. (Pubitemid 28487063)
40. Rantala AO, Lilja M, Kauma H, et al.: Gammaglutamyl trans-peptidase and the metabolic syndrome. J Intern Med 2000; 248:230-238.
41. Nakanishi N, Nishina K, Li W, et al.: Serum gamma-glutamyltransferase and development of impaired fasting glucose or type 2 diabetes in middle-aged Japanese men. J Intern Med 2003; 254:287-295. (Pubitemid 37070231)
42. Lee DH, Jacobs DR Jr, Gross M, et al.: Gamma-glutamyl transferase is a predictor of incident diabetes and hypertension: the coronary artery risk development in young adults (CARDIA) study. Clin Chem 2003; 49:1358-1366. (Pubitemid 36900623)
43. Cucuianu M: Serum γ-glutamyltransferase and/or serum Cholinesterase as markers of the metabolic syndrome (Letter). Diabetes Care 1999; 22:1381-1382.
44. Malnick SD, Beergabel M, Knobler H: Non-alcoholic fatty liver: a common manifestation of a metabolic disorder. QJM 2003; 96:699-709. (Pubitemid 37259360)
45. Hsueh WA, Quinones MJ: Role of endothelial dysfunction in insulin resistance. Am J Cardiol 2003; 92:10-17.
46. Whitfield JB: Gamma-glutamyl transferase. Crit Rev Clin Lab Sci 2001; 38:263-355.
47. Stark AA: Oxidative metabolism of glutathione by gamma-glutamyl transpeptidase and peroxisome proliferation: the relevance to hepatocarcinogenesis: a hypothesis. Mutagenesis 1991; 6:241-245.
48. Mohammad Alizadeh AH, Fallahian F, Alavian SM, et al.: Insulin resistance in chronic hepatitis B and C. Indian J Gastroenterol 2006; 25:286-289. (Pubitemid 46708823)
49. Wang CC, Hsu CS, Liu CJ, et al.: Association of chronic hepatitis B virus infection with insulin resistance and hepatic steatosis. J Gastroenterol Hepatol 2008; 23(5):779-782.
50. Czaja AJ, Carpenter HA: Sensitivity, specificity and predictability of biopsy interpretations in chronic hepatitis. Gastroenterology 1993; 105:1824-1832. (Pubitemid 24002801)
51. Thomopoulos KC, Arvaniti V, Tsamantas AC, et al.: Prevalence of liver steatosis in patients with chronic hepatitis B: a study of associated factors and of relationship with fibrosis. Eur J Gastroenterol Hepatol 2006; 18:233-237.
52. Bondini S, Kallman J, Wheeler A, et al.: Impact of non-alcoholic fatty live disease on chronic hepatitis B. Liver Int 2007; 27:607-611. (Pubitemid 47097309)
53. Day CP, James OF: Steatohepatitis: a tale of two 'hits'? Gastroenterology 1998; 114:42-45.
54. Marchesini G, Brizi M, Bianchi G, et al.: Non-alcoholic fatty liver disease: a feature of the metabolic syndrome. Diabetes 2001; 50(8):1844-1850. (Pubitemid 33641605)
55. Colin AB, Linda SA, Popkin BM: Ethnic differences in the association between body mass index and hypertension. Am J Epidemiol 2002; 155:346-353.
56. Grigorescu M, Radu C, Crisan D, et al.: Metabolic syndrome, insulin resistance and adiponectin level in patients with chronic hepatitis C. J Gastrointestin liver Dis 2008; 17(2):147-154. (Pubitemid 351930760)
57. Hui JM, Hodge A, Farrell GC, et al.: Beyond insulin resistance in NASH: TNF-alpha or adiponectin? Hepatology 2004; 40:46-54. (Pubitemid 38868922)
58. Gochee PA, Jonsson JR, Clouston AD, et al.: Steatosis in chronic hepatitis C: association with increased messenger RNA expression of collagen I, tumor necrosis factor-alpha and cytochrome P450 2E1. J Gastroenterol Hepatol 2003; 18:386-392. (Pubitemid 36549548)
59. Kamada Y, Tamura S, Kiso S, et al.: Enhanced carbon tetrachloride-induced liver fibrosis in mice lacking adiponectin. Gastroenterology 2003; 125:1796-1807. (Pubitemid 37500444)
60. Tietge UJ, Boker KH, Manns MP, Bahr MJ: Elevated circulating adiponectin levels in liver cirrhosis are associated with reduced liver function and altered hepatic hemodynamics. Am J Physiol Endocrinol Metab 2004; 287:E82-E89. (Pubitemid 38856286)
61. Petit JM, Minello A, Jooste V, et al.: Decreased plasma adiponectin concentrations are closely related to steatosis in hepatitis C virus-infected patients. J Clin Endocrinol Metab 2005; 90(4):2240-2243. (Pubitemid 40586268)
62. Tomita K, Oike Y, Teratani T, et al.: Hepatic AdipoR2 signaling plays a protective role against progression of non-alcoholic steatohepatitis in mice. Hepatology 2008; 48(2):458-473.